IMMunoglobulin G2
- CAS No.
- 1129435-60-4
- Chemical Name:
- IMMunoglobulin G2
- Synonyms
- Gevokizumab;IMMunoglobulin G2;Gevokizumab (anti-IL-1b);Research Grade Gevokizumab;Research Grade Gevokizumab(DHB95602)
- CBNumber:
- CB92563209
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | QX3JU54GYQ |
IMMunoglobulin G2 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Usbiological | 547630 | Immunoglobulin G2 PurifiedbyProteinA/Gaffinitychromatography. | 200ul | $553 | 2026-06-03 | Buy | |
| ChemScene | CS-0612591 | Gevokizumab 98.12% | 1129435-60-4 | 1mg | $238 | 2026-06-04 | Buy |
| ChemScene | CS-0612591 | Gevokizumab 98.12% | 1129435-60-4 | 5mg | $596 | 2026-06-04 | Buy |
| ChemScene | CS-0612591 | Gevokizumab 98.12% | 1129435-60-4 | 10mg | $953 | 2026-06-04 | Buy |
| aablocks | AA0093VB | IMMunoglobulin G2 ≥95%(SDS-PAGE&SEC-HPLC) | 1129435-60-4 | 1mg | $503 | 2026-05-28 | Buy |
IMMunoglobulin G2 Chemical Properties, Uses, Production
Uses
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II)[1][2].
in vivo
Gevokizumab (1 mg/kg; i.v.; once daily for 3 d) improves endothelial regrowth and reduces neointima formation in rats following carotid denudation[2].
| Animal Model: | Rat carotid denudation model in Sprague-Dawley rats (3-month0-old, 330-360 g)[2] |
| Dosage: | 1, 10 and 50 mg/kg |
| Administration: | Intravenous injection; once daily for 3 days |
| Result: | Decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery at day 28, and improved endothelial regrowth at 1 mg/kg. |
References
[1] Issafras H, et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties. J Pharmacol Exp Ther. 2014 Jan;348(1):202-15. DOI:10.1124/jpet.113.205443
[2] Roubille F, et al. The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis. 2014 Oct;236(2):277-85. DOI:10.1016/j.atherosclerosis.2014.07.012
IMMunoglobulin G2 Preparation Products And Raw materials
Raw materials
Preparation Products
IMMunoglobulin G2 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Shanghai Fuhe Chemistry Technology Co., Ltd. | 0086-21-67651709 | cfx759@hotmail.com | China | 409 | 57 |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
